aid: flare-therapeutics
name: Flare Therapeutics
description: >-
  Flare Therapeutics is a clinical-stage biotechnology company headquartered at 400 Technology
  Square, Cambridge, Massachusetts, developing small-molecule precision medicines against
  transcription factors — a target class long considered undruggable. Its platform combines a
  "switch site" hypothesis with cell-based ligand discovery and chemoproteomics to find binding
  pockets on transcription factors that control cancer cell states. The company launched publicly in
  May 2021 with an $82 million Series A led by Third Rock Ventures, and closed an $85 million
  insider-led Series C on 30 June 2026 led by Third Rock Ventures and Nextech Invest with Pfizer
  Ventures, Boxer Capital, GordonMD Global Investments, Invus, Casdin Capital, Eli Lilly, Novartis,
  Agent Capital and Eventide Asset Management participating, appointing Anna Protopapas as Chief
  Executive Officer at the same time. Its clinical-stage lead FX-909 is a PPARG inverse agonist in
  advanced urothelial cancer; FX-111 is an androgen-receptor-directed program in prostate cancer
  that received FDA IND clearance ahead of a clinical start in the third quarter of 2026. Flare also
  runs a discovery collaboration with Roche on undrugged transcription factor targets in oncology.
  Flare Therapeutics operates no developer program and publishes no product API, developer portal or
  API documentation. The only machine-readable surface reachable without credentials is the
  WordPress REST content API behind www.flaretx.com, catalogued here.
image: https://www.flaretx.com/wp-content/uploads/2021/05/Flare-website-social-card-051221.jpg
url: https://raw.githubusercontent.com/api-evangelist/flare-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enriched
specificationVersion: '0.23'
created: '2026-08-12'
modified: '2026-08-12'
tags:
- Company
- biotechnology
- pharmaceuticals
- oncology
- precision-medicine
- transcription-factors
- drug-discovery
- clinical-trials
- life-sciences
- content-api
apis:
- aid: flare-therapeutics:flare-therapeutics-content-api
  name: Flare Therapeutics Content API
  description: >-
    The anonymously readable WordPress REST content API behind www.flaretx.com — the 42-item
    corporate news archive, 14 corporate pages, a 419-item media library, the category taxonomy,
    cross-content search, type/taxonomy/status discovery documents and an oEmbed 1.0 provider
    endpoint. Flare Therapeutics publishes no OpenAPI for it; the specification in this repo is an
    API Evangelist derivation of the live route index, restricted to operations verified to return
    data anonymously on 2026-08-12.
  humanURL: https://developer.wordpress.org/rest-api/
  baseURL: https://www.flaretx.com/wp-json
  tags:
  - content
  - news
  - media
  - search
  properties:
  - type: OpenAPI
    url: openapi/flare-therapeutics-content-openapi.yml
  - type: Overlay
    url: overlays/flare-therapeutics-content-overlay.yaml
  - type: Authentication
    url: authentication/flare-therapeutics-authentication.yml
  - type: ErrorCatalog
    url: errors/flare-therapeutics-problem-types.yml
  - type: Conventions
    url: conventions/flare-therapeutics-conventions.yml
  - type: DataModel
    url: data-model/flare-therapeutics-data-model.yml
  - type: Lifecycle
    url: lifecycle/flare-therapeutics-lifecycle.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/flare-therapeutics-domain-security.yml
- type: Website
  url: https://www.flaretx.com/
- type: About
  url: https://www.flaretx.com/about/
- type: Science
  url: https://www.flaretx.com/science/
- type: Pipeline
  url: https://www.flaretx.com/pipeline/
- type: Publications
  url: https://www.flaretx.com/publications/
- type: News
  url: https://www.flaretx.com/news/
- type: BlogRSS
  url: https://www.flaretx.com/feed/
- type: Careers
  url: https://www.flaretx.com/join-us/
- type: Contact
  url: https://www.flaretx.com/contact/
- type: PrivacyPolicy
  url: https://www.flaretx.com/privacy-policy/
- type: TermsOfService
  url: https://www.flaretx.com/terms-of-use/
- type: LinkedIn
  url: https://www.linkedin.com/company/flare-therapeutics
- type: GitHubOrganization
  url: https://github.com/FlareTx
- type: SecondaryMarket
  url: https://forgeglobal.com/flare-therapeutics_stock/
- type: Authentication
  url: authentication/flare-therapeutics-authentication.yml
- type: Conventions
  url: conventions/flare-therapeutics-conventions.yml
- type: Conformance
  url: conformance/flare-therapeutics-conformance.yml
- type: ErrorCatalog
  url: errors/flare-therapeutics-problem-types.yml
- type: Lifecycle
  url: lifecycle/flare-therapeutics-lifecycle.yml
- type: DataModel
  url: data-model/flare-therapeutics-data-model.yml
- type: LLMsTxt
  url: llms/flare-therapeutics-llms.txt
- type: AgentSkill
  url: skills/_index.yml
x-enrichment:
  date: '2026-08-12'
  status: enriched
  artifacts_added: 17
  pass: local-v1